Evidence map›Paper›PMID 34744423›Full record

ArticleSarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG2021

Sertraline-Associated Interstitial Lung Disease: A case series and Literature Review.

Shimon Izhakian, Dror Rosengarten, Barak Pertzov, Ahuva Grubstein, Moshe Heching, Ludmila Fridel, Mordechai R Kramer

Open access · greenAbstract read
In one paragraph

Article in Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Interstitial lung disease in psoriasis: A systematic review and meta-analysis.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Shimon IzhakianPulmonary Institute, Rabin Medical Center, Petah Tikva, Israel.
Dror RosengartenPulmonary Institute, Rabin Medical Center, Petah Tikva, Israel.
Barak PertzovPulmonary Institute, Rabin Medical Center, Petah Tikva, Israel.
Ahuva GrubsteinSackler Faculty of Medicine, Tel Aviv University, Ramat Aviv, Israel.
Moshe HechingPulmonary Institute, Rabin Medical Center, Petah Tikva, Israel.
Ludmila FridelSackler Faculty of Medicine, Tel Aviv University, Ramat Aviv, Israel.
Mordechai R KramerPulmonary Institute, Rabin Medical Center, Petah Tikva, Israel.
Tel Aviv University · ILRabin Medical Center · IL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sertraline-associated interstitial lung disease (ILD) is a rare entity. A search of the English medical literature retrieved only 9 such cases. We report herein on an additional 12 patients who developed ILD during treatment with sertraline. The patients met the criteria for drug-induced pulmonary toxicity such as exposure to drug, correlation of the drug with clinical symptoms, lung imaging, lung biopsy findings, exclusion of other potential causes and improvement after drug removal. We review the available data and discuss various aspects of this entity. The possibility of drug-induced ILD should be considered in an individual who during treatment with sertraline develops dyspnea, cough, and radiographic findings compatible with ILD. Further epidemiological studies should be conducted to explore the association of sertraline treatment with ILD, and to delineate, substantiate, and broaden our knowledge of this rare entity.

Indexed as

Interstitial lung diseasePulmonary fibrosisSertralineSSRI

Identifiers

PMID34744423
PMCPMC8552566
OpenAlexW3211770556

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.